From: Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
Unique compounds per MoA (current pipeline 02–27) | Phase 1 | Phase 2 | Phase 3 | Total |
---|---|---|---|---|
Symptomatic for cognition | 5 | 10 | 10 | 25 |
Symptomatic for behavior | 2 | 3 | 4 | 9 |
Disease-modifying small molecule (amyloid-related) | 4 | 5 | 1 | 10 |
Disease-modifying small molecule (tau-related) | 3 | 0 | 1 | 4 |
Disease-modifying small molecule (neuroprotector) | 2 | 19 | 4 | 25 |
Disease-modifying immunotherapy | 4 | 8 | 3 | 15 |
Therapeutic device | 2 | 4 | 0 | 6 |
Stem cells | 0 | 1 | 0 | 1 |
Total | 22 | 50 | 23 | 95 |